the aid library

LIST OPTIONS

Filter

691

Sort by:

Direction:

Download (36)

View PDF (30)

how to use your pump correctly - Outcome of illustrated information leaflet on correct usage of asthma - metered dose inhaler

Wrench, W.; van Dyk, L.; Sirinivas, S.; Dowse, R. (2019) CC2

Research globally has shown that metered dose inhaler (MDI) technique is poor, with patient education and regular demonstration critical in maintaining correct use of inhalers. Patient information containing pictorial aids improves understanding of medicine usage; however, manufacturer leaflets i... more

Download (34)

View PDF (43)

Asthma and pregnancy

National Asthma Education Programme (2012) CC2

Asthma can be a serious disease, but if you understand the disease and take the right medication to control it, you should have no problems or symptoms due to your asthma, even when you are pregnant. To be free from asthma attacks, you should also check your lung function and use an action plan... more

Download (30)

View PDF (27)

Sport and Asthma

Green, R.; Nagel, F. National Asthma Education Programme (2012) CC2

People with asthma should be encouraged to take part in any sport they choose. If someone with asthma is having difficulty with sport, it means their asthma may not be under control. You will need to see your doctor to review your controller treatment and the way you use your medications in oder to ... more

Download (34)

View PDF (29)

Asthma Myths

Allergy Foundation South Africa (2018) CC2

Myth: It’s better to ‘tough it out’ without taking asthma medication. The lungs do not get stronger or become better able to deal with asthma if a person tries to work through an attack without medication. In fact, the lung inflammation that goes along with an attack (see what is asthma) ... more

Download (43)

View PDF (114)

A summary of the new GINA strategy: a roadmap to asthma control

Reddel, H. K.; Bateman, E. D.; Becker, A.; et al. (2015) CC2

Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many national guidelines. However, uptake of existing guidelines is poor. A major revision of the GINA r... more

Download (40)

View PDF (84)

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Chung, K. F.; Wenzel, S. E.; Brozek, J. L.; et al. (2022) CC2

The European Respiratory Society (ERS)/American Thoracic Society (ATS) Task Force on severe asthma includes an updated definition of severe asthma, a discussion of severe asthma phenotypes in relation to genetics, natural history, pathobiology and physiology, as well as sections on evaluation and tr... more

Download (35)

View PDF (117)

Global Strategy for Asthma Management and Prevention (2022 update)

Global Initiative for Asthma (2022) CC2

The reader acknowledges that this report is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessi... more

Download (38)

View PDF (142)

Global Strategy for Asthma Management and Prevention (2019 update)

Global Initiative for Asthma (2019) CC2

Download (55)

View PDF (106)

2020 Brazilian Thoracic Association recommendations for the management of asthma

Menezes Pizzichini, M. M.; de Carvalho-Pinto, R. M.; Delfini Cançado, J. E.; et al. (2020) CC2

The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... more

Download (53)

View PDF (49)

Pediatric Asthma: A Global Epidemic

Serebrisky, D.; Wiznia, A. Annals of Global Health (2019) CC

The global prevalence, morbidity and mortality related to childhood asthma among children has increased significantly over the last 40 years. Although asthma is recognized as the most common chronic disease in children, issues of underdiagnosis and undertreatment persist. There are substantial globa... more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (253)

View PDF (251)

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended

World Health Organization WHO (2022) C_WHO

Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi... more

Download (167)

View PDF (196)

WHO pharmaceuticals newsletter - No. 1, 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world. In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f... more

Download (650)

View PDF (367)

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

World Health Organization WHO (2022) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (499)

View PDF (1007)

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
recommended

World Health Organization (WHO) (2022) C_WHO

Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa. These guidelines update the recommendations that were first released i... more

Download (299)

View PDF (264)

Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente

Organización Mundial de la Salud OMS (2022) C_WHO

Las recomendaciones contenidas en este módulo son un componente de las directrices unificadas de la OMS sobre la tuberculosis (TB) y están destinadas principalmente para el uso de los programas nacionales de control de la tuberculosis, los organismos de salud pública y otros interesados clave que... more

Download (298)

View PDF (274)

Guidelines for the clinical management of severe illness from influenza virus infections

World Health Organization WHO (2022) C_WHO

Download (164)

View PDF (201)

COVID-19 clinical care pathway (‎CARE)‎: confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery

World Health Organization WHO (2022) CC

The COVID-19 CARE pathway is a living tool to support health care workers visualize the current clinical and therapeutic recommendations to be considered in the care planning for patients with COVID-19. The COVID-19 CARE pathway is aligned with the eighth version of the WHO Therapeutics and COVID... more

Download (137)

View PDF (177)

Enhancing response to Omicron SARS-CoV-2 variant

World Health Organization WHO (2022) C_WHO

21 January 2022 The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian... more

Download (173)

View PDF (136)

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended

WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
recommended